All In Biotech

Drug Trial Radar · NCT06411899

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 422 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

422

Actual

Start

May 15, 2024

Primary completion

Sep 2, 2025

Study completion May 14, 2026

Sponsor

Lead sponsor
MoonLake Immunotherapeutics AGIndustry
Sponsor type
Industry
First posted
May 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • SonelokimabDrug

    Sonelokimab

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hidradenitis Suppurativa Clinical Response 75Time frame: Week 16

Locations

109 sites in 10 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Los Angeles, California

  • Clinical Site

    Northridge, California

  • Clinical Site

    Sacramento, California

  • Clinical Site

    San Diego, California

  • Clinical Site

    Coral Gables, Florida

  • Clinical Site

    Coral Springs, Florida

  • Clinical Site

    Hollywood, Florida

  • Clinical Site

    Margate, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Tampa, Florida

  • Clinical Site

    Macon, Georgia

  • Clinical Site

    Sandy Springs, Georgia

  • Clinical Site

    West Dundee, Illinois

  • Clinical Site

    Columbus, Indiana

  • Clinical Site

    New Albany, Indiana

  • Clinical Site

    Louisville, Kentucky

  • Clinical Site

    Metairie, Louisiana

  • Clinical Site

    Boston, Massachusetts

  • Clinical Site

    Boston, Massachusetts

  • Clinical Site

    Dearborn, Michigan

  • Clinical Site

    Warren, Michigan

  • Clinical Site

    Las Vegas, Nevada

  • Clinical Site

    New York, New York

  • Clinical Site

    The Bronx, New York

  • Clinical Site

    Boardman, Ohio

  • Clinical Site

    Dayton, Ohio

  • Clinical Site

    Mayfield Heights, Ohio

  • Clinical Site

    Oklahoma City, Oklahoma

  • Clinical Site

    Charleston, South Carolina

  • Clinical Site

    Nashville, Tennessee

  • Clinical Site

    Frisco, Texas

  • Clinical Site

    Houston, Texas

  • Clinical Site

    Houston, Texas

  • Clinical Site

    South Jordan, Utah

  • Clinical Site

    Forest, Virginia

  • Clinical Site

    Mill Creek, Washington

  • Clinical SIte

    Pleven, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.